About
Antipsychotic medications are commonly used to manage psychotic disorders including schizophrenia and bipolar disorder; however these medications can cause serious side effects such as weight gain, and ultimately, metabolic syndrome. Despite the severity of psychotic disorders, metabolic syndrome is the leading cause of morbidity and mortality in patients with schizophrenia. Guidelines relevant to primary and psychiatric care recommend metformin to manage antipsychotic-induced weight gain (AIWG). Metformin is affordable, well-tolerated and effective for reducing AIWG, yet is not routinely prescribed alongside antipsychotics. This project aims to collaborate with psychiatrists, family doctors, allied health professionals, and patients with psychotic disorders to understand the gaps in care for antipsychotic-induced weight gain.
Impact
This project will influence the healthcare system by bringing together different specialties, namely family medicine and psychiatry, to provide comprehensive care with a focus beyond treating the mental illness alone. It will help clarify the responsibility of AIWG between two specialties. This project will be guided by perspectives of those with lived experience of psychotic disorders. It will influence patient care by prioritizing a holistic approach to antipsychotic prescribing, with an emphasis on not only treating, but preventing AIWG.
(Header photo credit: Unsplash)